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Abstract
Coronavirus disease 2019 (COVID-19) is a major issue of our times. Many 
aspects and features of this new and complex disease are being described on a 
daily basis. Major endpoints are systemic inflammation, markedly characterized 
by the cytokine storm, respiratory failure, and coagulation disorders, such as 
thrombophilia. In its terms, thrombophilia has a major impact on the COVID-19 
prognosis. With regard to this, paying attention on molecular variants, such as 
DNA polymorphisms, epigenetic factors, and other biomarkers, could be an 
important approach to optimizing and personalizing the treatment of patients 
according to their inherited thrombotic features. This chapter brings an overview 
on the three major DNA polymorphisms associated with thrombophilia and 
proposes that these same biomarkers could be used in pretreatment screenings of 
patients with COVID-19 to seek the most appropriate therapy for each individual 
molecular profile.
Keywords: COVID-19, coagulation, thrombophilia, biomarkers,  
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1. Introduction
One of the major issues of the 21st century, without any doubt, is the viral 
respiratory disease discovered at the end of 2019, the COVID-19. Using next-
generation sequencing, the pathogen related to COVID-19 was described as a novel 
coronavirus, which is related to the SARS-coronavirus described in 2003, mainly in 
Asia, from the molecular and phylogenetic aspects [1].
A severe respiratory disease was reported in Wuhan, Hubei province, China. 
Epidemiological investigations have suggested that the outbreak was associated 
with a seafood market in Wuhan [2].
The first case reported in the medical literature was that of a 41-year-old 
man who was hospitalized in the Central Hospital of Wuhan. The patient was 
admitted to the hospital reporting an extensive set of symptoms since one week 
before his admission on December 26, 2019, which included dry cough without 
sputum, fever, weakness, chest tightness, and widespread pain. Normal signs were 
observed at physical examination on abdominal, cardiovascular, and neurological 
features.
Biomarkers and Bioanalysis Overview
2
2. General aspects on COVID-19 diagnosis
Among the biomarkers analyzed, one of the most important findings was the 
raised C-reactive protein (CRP) level of 41.4 mg/L (standard at 0–6 mg/L) whose 
circulating concentrations rise in response to inflammation. Followed by the higher 
CRP, the biochemistry cardiac panel also showed raised myocardial infarction 
markers, such as lactic dehydrogenase (LDH), aspartate aminotransferase (AST), 
and creatine kinase (CK). Taken together, these biomarkers strongly indicated a 
severe acute inflammatory phase with the ongoing cardiac effect to be controlled. 
Mild lymphopenia with less than 9 × 10e5 cells per mL with normal platelet counts 
completes the first patient’s overview [2].
Pulmonary function and lung aspects were investigated in this patient in order to 
do the etiological diagnosis. Hypoxemia was observed according to oxygen levels of 
67 mm Hg. Lungs’ aspect was set by chest radiographs on day 1 of hospital admis-
sion, which was the 6th day of disease progression. The images showed abnormal 
features with focal and patchy consolidation in both lungs, beyond air-space 
shadowing such as ground-glass like opacities [2].
Image examination of the chest shows a consolidation pattern at computed-
tomography (CT) scans: bilateral focal consolidation, lobar consolidation, and 
patchy consolidation, especially in the lower lung. Five days after admission, at 
the 11th day of disease progression, a chest radiograph revealed a bilateral diffuse 
patchy and fuzzy shadow [2].
With the advancement of the pandemic, what was seen as a respiratory disease 
became a more complex disease and new studies were set up to list other complica-
tions and associated risk factors.
3. Potential impact of thrombotic complications on COVID-19 prognosis
Many factors can contribute to increasing the risk for severe COVID-19, in some 
cases followed to death. The main comorbidities described are high age, obesity, 
diabetes, and hypertension. Beyond the inflammation and impaired coagulation, 
focal damage in some tissues/organs is also related to the COVID-19 spectrum, such 
as liver, kidney, and heart [3].
Thrombotic complications seem to emerge as an important issue in patients 
infected with COVID-19. Preliminary reports on COVID-19 patients’ clinical and 
laboratory findings include thrombocytopenia, elevated D-dimer, prolonged 
prothrombin time, and disseminated intravascular coagulation.
In the course of the COVID-19 studies, a clear association with coagulation 
dysfunction was pointed in many cases. Intra-alveolar clots were prominent find-
ings in COVID-19 patients who developed severe respiratory disease. The same 
findings have been described in both clinical and animal model studies. Apparently, 
an impaired response in the prothrombotic pathway is in charge of diffuse alveolar 
hemorrhage since it is related to overt clot formation [4].
In the recent publication “Should COVID-19 be branded to Viral Thrombotic 
Fever?,” the authors intended to frame COVID-19 in more clinical terminology, 
making an analogy to Viral Hemorrhagic Fever (VHF). In this article, the authors 
reported: “We found irrefutable evidence in the current literature that COVID-
19 is the first viral disease that can be marketed as a viral thrombotic fever” [5]. 
Although this is a very categorical statement, considering the small number of 
studies exclusively dedicated to the characterization of COVID-19 as a thrombotic 
fever, it is very important to consider this designation. Categorizing COVID-19 as 
a febrile variant of thromboembolism adds a series of procedures to be adopted in 
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patients’ care. This approach can advance the treatment adequacy by many steps, 
making it as more personalized as possible.
4.  DNA polymorhisms for a pharmacogenonic approach to COVID-19 
treatment
The risk of thromboembolism in COVID-19 is documented in an article pub-
lished in The Lancet [6]. This finding brings up an important issue to be screened on 
COVID-19 patients: the impact of inherited predisposition to thrombotic events in 
patients affected by COVID-19.
Given this, thrombophilic genetic abnormalities in variants were widely reported 
in the medical sciences such as Factor V Leiden (F5), Prothrombin (F2), and the 
polymorphism in methylenetetrahydrofolate reductase (MTHFR), among others 
[7]. These polymorphisms could put a patient’s carriers of mutant alleles in the 
Risk Group, beyond the well-known factors, such as elderly patients, hypertension, 
cardiac and respiratory diseases, cancer, and diabetes [8].
In this chapter, we present a brief review of the three main DNA polymorphisms 
associated with thrombophilic events and suggest the inclusion of these, as well as 
the coagulation profiles of their carriers, as aggravating comorbidities of COVID-19.
Firstly, a brief review of the main molecular characteristics of these polymor-
phisms is as follows:
4.1 Factor V Leiden (FVL or F5)
It represents one of the main causes of resistance to protein C, as mutation 
increases the risk of thrombotic disease three to ten times for heterozygous carriers 
and eighty times for homozygous carriers [4, 9]. About 90% of cases of protein C 
resistance result from point mutation in the coagulation factor V gene. This muta-
tion occurs in exon 10 of the factor V gene, causing a substitution of the G/A base 
(Guanine/Adenine) in nucleotide 1691, resulting in the exchange of Arg (Arginine) by 
Gln (Glutamine) at position 506 of the protein, one of the main cleavage sites for pro-
tein C activation [10]. FVL is the most common inherited cause of venous thrombosis.
In patients with increased protein C resistance, venous thrombosis without 
known etiology and familiar history of unexplained thrombosis, the FVL muta-
tions’ screening should be considered beyond a strong clinical investigation. The 
diagnosis for FVL mutations is based on well-known molecular biology approaches. 
The clotting time-based functional assays and genetic biomarkers’ screening 
become together the basis for clinical decisions. It is a very important step to guide 
the clinical approach, balancing the long-term anticoagulation with its side effects 
and benefits [11].
Briefly, the mechanism of action of factor V could be described as follows. 
Factor V is cleaved by thrombin on its B domain at cleavage sites R709, R1018, and 
R1545, producing an amino-terminal heavy chain and a carboxy-terminal light 
chain, which binding themselves create a dimer called Factor Va (FVa). In turn, 
FVa binds with Factor Xa creating a prothrombinase complex which on the platelet 
surface converts prothrombin (II) to thrombin (IIa). FV can also be split by the 
action of activated protein C (APC) at the cleavage site R506 before it is cleaved by 
thrombin. It results in the inactivation of factor V to factor Vi and the generation of 
an imperfect peptide, the Factor Vac, which apparently has anticoagulant charac-
teristics by stimulating APC- and protein S-mediated inactivation of factor VIIIa. 
A second mechanism of thrombosis observed with FVL is its diminished cofactor 
activity with APC and phospholipid in the inactivation of factor VIIIa to factor 
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VIIIi. Taken together, FVL is a prothrombotic mutation due to a combination of a 
gain of function, with higher prothrombin activation, and loss of function due to 
low cofactor activity with APC in the inactivation of factor VIIIa. Normally, patients 
with defective FVL have a variable thrombophilia phenotype, have increased 
thrombin generation, have a longer factor Va half-life in plasma, and are resistant to 
factor Va inactivation [11]. A larger C-terminal peptide results if factor V is cleaved 
by APC before it is cleaved by thrombin [12].
4.2 Prothrombin (PTB, factor 2 or F2)
The G20210A mutation of prothrombin causes a G to A transition at the nucleo-
tide position 20,210. This mutation increases circulating prothrombin activity and 
levels [13]. PTB is a vitamin K-dependent coagulation factor, which in its active 
form is cleaved, forming in this way the thrombin. The thrombin catalyzes many 
other coagulation-related reactions and acts as a serine protease that converts 
fibrinogen to fibrin. PTB mutations are the second-most common inherited throm-
bophilia. In the United States, the heterozygous carrier frequency is about 1–2%, 
accounting for approximately 6–18% of VTE cases. Hyperthrombinemia has been 
associated with a mutation in the 3′ termination of the PTB gene, called c.∗97G > A, 
which results in increased production, due to the increased PTB mRNA expression 
and stabilization. An increased amount of circling prothrombin can lead to higher 
thrombin generation in the plasma, followed by coagulation activation and throm-
bosis. This mutation is also more common in the Caucasian population and is rare in 
other ethnic groups. Homozygosity, for this mutation, is found in about 1 in 10,000 
individuals. Transheterozygosity for FVL and prothrombin c.∗97G > A affects about 
1 in 1000 individuals. Additional variations identified in the 3′-untranslated region 
of the prothrombin gene include changes at positions 20,207, 20,209, 20,218, and 
20,221. High PTB levels also inhibit APC-mediated inactivation of activated FV and 
factor VIII. The prevalence of prothrombin G20210A mutation varies in differ-
ent countries and ethnic groups, being highest in Caucasians, especially those in 
Southern Europe, and in the Mediterranean region [14].
4.3 Polymorphism in the MTHFR enzyme
Hotoleanu, in his article Genetic Risk Factors in Venous Thromboembolism, 
described that MTHFR acts on homocysteine metabolism, reducing 
5.10-Methylenetetrahydrofolate to 5-methylenetetrahydrofolate. The enzyme 
polymorphisms generally occur at two sites, at position C677T, which character-
izes the substitution of alanine for valine at codon 222, and at position A1298C, 
which occurs due to the substitution of glutamine for alanine at codon 429, the 
second mutation being less aggressive than C677T, which is homozygous and in 
the presence of low levels of folate decreases enzyme activity leading to hyperho-
mocysteinemia, a risk factor for thrombophilia [15].
Simoni et al. corroborate this theory, when they describe that mutations in the 
MTHFR enzyme reduce its activity leading to hyperhomocysteinemia. Increase in 
homocysteine levels is a risk factor for thromboembolism [16].
Considering patients with COVID-19, especially those seriously ill, there are 
several potential risk factors for venous thromboembolism, including infection, 
immobilization, respiratory failure, mechanical ventilation, and use of a central 
venous catheter [17, 18]. Wang et al. reported in their Lancet article that patients 
at a high risk for venous thromboembolism had worse results with COVID-19 than 
patients at a low risk for venous thromboembolism, suggesting that these patients 
may require more attention in the event of rapid deterioration [6].
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A systematic review and meta-analysis done to analyze the thromboembolism 
risk on COVID-19 patients showed that its occurrence is high and associated with 
the worst clinical development. A total of 8271 patients from 425 eligible studies 
were included in the meta-analysis. In summary, the data set showed that COVID-19 
patients had a higher risk of mortality, as described in Table 1 [19].
Our suggestion of early detection and greater attention in COVID-19 patients 
with aggravating factors of thromboembolism may be addressed to the data found 
by Wang and colleagues [6]. Considering the correct prophylaxis, the majority of 
the venous thromboembolism occurrences could be prevented, mainly on patients 
with a higher risk for it. In spite of that, from the 140 patients investigated in the 
cohort, only 7% (10 patients) were maintained under anticoagulant therapy during 
their hospitalization. Among them, one received rivaroxaban and nine received 
heparin. It is a low proportion compared to the total number of patients with high 
risk to develop venous thromboembolism in their cohort. This finding possibly 
indicates that the prophylactic approach applied in the patients with COVID-19 was 
not adequate.
Other coagulation disorders observed in patients with COVID-19 also support 
the idea that a preliminary analysis of the genetic factors involved may better guide 
the therapeutic approach to be adopted. COVID-19-associated coagulopathy and 
disseminated intravascular coagulation (DIC) are being described as common 
findings in these patients. It is known that the pathophysiology of DIC associated 
with COVID-19 differs from that of septic DIC, and in this context both thrombotic 
and hemorrhagic pathologies must be observed. Thrombosis events in COVID-19 
include macrothrombosis (MAT) and microthrombosis (MIT), and it is important 
to note that the diagnosis of MIT depends on coagulation and fibrinolysis markers. 
Consequently, molecular nuances can have a major impact on the worsening of the 
thrombohemorrhagic condition in different individuals [20, 21].
5. Conclusion
Screening and inclusion of COVID-19 patients with genetic abnormalities 
in thrombophilic conditions could guide the medical team to identify possible 
aggravating complication factors even if their patients are not in the group pre-
determined risk, described by the World Health Organization (WHO) [8].
Overall venous thromboembolism (TE): 21% (95% CI: 17–26%)
ICU: 31% (95% CI: 23–39%)
Overall deep vein thrombosis rate: 20% (95% CI: 13–28%)
ICU: 28% (95% CI: 16–41%)
Postmortem: 35% (95% CI: 15–57%)
Overall pulmonary embolism rate: 13% (95% CI: 11–16%)
ICU: 19% (95% CI: 14–25%)
Postmortem: 22% (95% CI: 16–28%)
Overall arterial TE rate: 2% (95% CI: 1–4%)
ICU: 5% (95% CI: 3–7%)
Pooled mortality rate among patients with TE: 23% (95% CI: 14–32%) and
Pooled mortality rate among patients without TE: 13% (95% CI: 6–22%)
The pooled odds of mortality among patients who developed TE was 4% higher compared to those who did 
not (OR: 1.74; 95% CI: 1.01–2.98; P = 0.04)
Table 1. 
Summary of the data set described by Malas et al. [19].
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The treatment of COVID-19 is based on antiviral therapy, treatment to contain the 
cytokine storm, and treatment of thrombosis. Rather than providing uniform treat-
ment, a method best suited for severity and stage should be selected. Considering the 
molecular profile of each individual can be an important tool in this race against time 
that characterizes care for patients with COVID-19. In this scenario, COVID-19 could 
be another exponent for a pharmacogenomics approach to the treatment of human 
diseases and it proved to be a challenge for humanity in the 21st century. The com-
plications, sequels, and deaths took on catastrophic proportions. Despite the speed 
with which a significant range of vaccines were presented, comprehensive coverage 
worldwide is likely to face dares.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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